140 related articles for article (PubMed ID: 22119201)
21. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
[TBL] [Abstract][Full Text] [Related]
22. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
23. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
24. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
25. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M
Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308
[TBL] [Abstract][Full Text] [Related]
26. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
27. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Gansmo LB; Romundstad P; Birkeland E; Hveem K; Vatten L; Knappskog S; Lønning PE
Cancer Med; 2015 Dec; 4(12):1901-7. PubMed ID: 26471763
[TBL] [Abstract][Full Text] [Related]
28. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G
Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402
[TBL] [Abstract][Full Text] [Related]
29. A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients.
Pan X; Li Y; Feng J; Wang X; Hao B; Shi R; Zhang G
BMC Cancer; 2013 Mar; 13():126. PubMed ID: 23506213
[TBL] [Abstract][Full Text] [Related]
30. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
[TBL] [Abstract][Full Text] [Related]
31. The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome.
Renaux-Petel M; Sesboüé R; Baert-Desurmont S; Vasseur S; Fourneaux S; Bessenay E; Frébourg T; Bougeard G
Fam Cancer; 2014 Mar; 13(1):127-30. PubMed ID: 23884452
[TBL] [Abstract][Full Text] [Related]
32. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
33. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
34. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
35. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients.
Phang BH; Linn YC; Li H; Sabapathy K
Eur J Cancer; 2008 Mar; 44(5):760-6. PubMed ID: 18313915
[TBL] [Abstract][Full Text] [Related]
36. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
[TBL] [Abstract][Full Text] [Related]
37. Association of the
Wang P; Wang M; Li S; Ma L; Xi S; He J
Dis Markers; 2016; 2016():4585484. PubMed ID: 27890964
[TBL] [Abstract][Full Text] [Related]
38. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
39. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
40. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter.
Petz LN; Nardulli AM
Mol Endocrinol; 2000 Jul; 14(7):972-85. PubMed ID: 10894148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]